Drug Profile
Research programme: mdm2 inhibitors - Priaxon/NexusPharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Priaxon
- Developer NexusPharma; Priaxon
- Class
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 17 Apr 2009 Preclinical trials in Cancer in Germany (PO)